Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Immune Pathway Identified That Prevents C. albicans Infection from Becoming Deadly

Published

on

King’s College London researchers have identified an immune pathway that prevents what is normally a harmless fungus, Candida albicans, from developing into a fatal infection.

The team’s study, including experiments in mice, identified a central role for the IL-1 family in mediating rapid and protective immunity against C. albicans mucosal infection. If the results of the preclinical study are confirmed in humans, they could help better understand who is at risk of developing fatal fungal infections and also point to a potential therapeutic target.

The results provide the first potential clues as to why only some patients with weakened immune systems—including those undergoing chemotherapy or living with HIV—are at risk of life-threatening Candida albicans infection. James S. Griffiths, PhD, research fellow, King’s College London, said, “Most people carry Candida albicans harmlessly as part of the body’s natural microbiome, but in immunocompromised patients it can spread throughout the body and become life-threatening. A major challenge has been understanding why a fungus that is normally harmless can suddenly spread beyond its natural niche and cause invasive disease. Our study identified the IL-1 family as a critical early immune defense system that helps prevent this fungus from escaping the mouth and gut and spreading to multiple organs. We hope these findings will help identify patients at greatest risk of invasive fungal disease and provide a foundation for developing new ways to strengthen protective antifungal immunity.”

Griffiths is corresponding author of the team’s published paper in Nature Microbiology, titled “IL-1 family signaling drives mucosal defense against systemic Candida albicans infection.”

C. albicans is a fungus that normally lives harmlessly in the mouth and gut but can sometimes spread through the body and cause fatal disease. Fungal infections kill more than 2.5 million people each year, and C. albicans alone kills almost a million. “While mucosal infection is common and contributes to morbidity, it is invasive systemic disease that drives mortality,” the authors explained.

However, scientists haven’t fully understood why fungi can escape their natural locations in the mouth and gut and cause life-threatening disease in around 10% of patients who have a weakened immune system. “With increasing resistance to antifungals, poor diagnostic tools and limited therapeutics, understanding how C. albicans mucosal infections develop and, critically, how they disseminate, is vital to managing C. albicans disease,” the investigators continued.

For their reported study they focused on a signal, IL-1, produced by the immune system to trigger symptoms to fight off infection. IL-1 family members are potent regulators of immunity, the investigators noted, and both insufficient IL-1 activity, and excessive activity, may be implicated in disease. “Here, we investigated how the combinatorial IL-1 family shapes the host immune response to mucosal C. albicans infection and explored the role of the IL-1 family in mucosal–systemic dissemination,” they noted.

The scientists’ study showed that mice genetically modified not to produce IL-1 experienced severe disease when exposed to Candida albicans. The study results suggested that the IL-1 immune pathway is critical in preventing Candida albicans from spreading around the body and causing life-threatening disease.

The team investigated this further by injecting IL-1-deficient mice with a drug that removes neutrophils, a type of white blood cell that is among the first to respond to infections and help fight threats such as bacteria and fungi. This approach allowed the researchers to mimic the weakened immune system seen in some immunocompromised patients. By then introducing Candida albicans to the mouths of those mice, the scientists for the first time observed the fungus spread throughout the body and cause fatal disease, confirming that IL-1 is critical in preventing disease spreading. “Critically, absence of IL-1 family signaling coupled with neutropenia permits C. albicans dissemination from the mucosa, first to the liver and then into multiple organs, mimicking disease experienced by severely immunocompromised patients,” they reported.

While the study focused specifically on Candida albicans, the researchers say the IL-1 immune pathway may be a broader defense mechanism that helps keep fungi normally found in healthy microbiomes from spreading and causing fatal disease, and further research is needed to confirm whether this applies to other fungal species. Understanding what causes fungi that are naturally present in our microbiomes, such as Candida albicans, to cause life-threatening disease could help spot at-risk patients earlier.

The researchers suggest that, if confirmed in humans, the findings could lead to a test that identifies which immunocompromised patients have low levels of IL-1 and so are at heightened risk of Candida albicans escaping their microbiomes and causing disease.

While drugs such as antibiotics are currently used to treat life-threatening fungal diseases, more targeted therapies are needed that tackle the root cause of infection. The researchers suggest future clinical studies in humans could test whether drugs targeting IL-1 could work as a personalized therapy for preventing life-threatening Candida albicans infection.

Co-author Lea Lortal, PhD, a postdoctoral researcher in mycology at the University of California, San Francisco (UCSF), said, “Fungal infections are severely overlooked: they affect more than one billion people worldwide. Yet, there are still no clinically approved vaccines against any fungal pathogen, and our understanding of the immune mechanisms that protect us from fungal disease remains incomplete. What normally keeps fungi, such as Candida albicans, in check has remained a major unanswered question. In this study, we identified the IL-1 family as a key early coordinator of the immune response that helps contain Candida before it can become invasive. Understanding how these protective responses are initiated is an important step toward developing better ways to prevent and treat invasive fungal infections.”

In summary, the authors wrote, “Our findings suggest that combinatorial IL-1 family function plays a crucial role in dissemination risk, offering potential for a personalized therapeutic approach. Consequently, therapeutically enhancing IL-1 family function to augment mucosal immunity and reduce dissemination could have substantial clinical implications.”

The post Immune Pathway Identified That Prevents <i>C. albicans</i> Infection from Becoming Deadly appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID

Published

on

Chronically infecting viruses—such as Epstein Barr, cytomegalovirus, and herpes virus—are ubiquitous in humans. Although their presence is often innocuous and asymptomatic, the viruses can reactivate during stress, and emerging evidence suggests that their reactivation may contribute to autoimmune disease and other chronic conditions. SARS-CoV-2 infection is known to reactivate some chronic viruses, yet the full extent of the effects is not well understood.

Now, a study including 15 biomedical research institutions across the United States, Boston Children’s Hospital researchers and their collaborators have discovered that COVID-19 reactivates certain dormant viruses in hospitalized patients. These findings expand understanding of chronically infecting viruses and could inform development of strategies to combat their reactivation.

This work is published in a new study in Nature, entitled, “Virus reactivation in acute and long COVID-19.”

The study leveraged multiomic longitudinal data of 1,154 patients with COVID-19 from the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study across 20 U.S. biomedical research hospitals. It was designed to define biomarkers of COVID-19 severity and outcomes.

“This is the largest and most comprehensive biomarker study of COVID-19, in which we followed more than one thousand patients, collected more than 200,000 samples, and generated more than one billion data points over the course of a year for this public resource,” says Joann Diray Arce, PhD, who leads the PVP-Data Management and Analysis Core and is the lead of the study’s Clinical and Data Coordinating Center.

The research team detected 11 reactivated viruses in patients within the first 40 days from admission, with the most detected ones being Epstein-Barr, herpes simplex 1, cytomegalovirus, and Anelloviridae viruses. Notably, reactivation of Anelloviridae, a poorly understood family of viruses typically latent in about 90 percent of the population, was associated prominently with long-term physical disability and long COVID.

“This association with long COVID is an interesting finding as millions around the world suffer from this chronic condition,” says Ofer Levy, MD, PhD, director of the Precision Vaccines Program (PVP) at Boston Children’s. “Having new insight as to the molecular and viral associations with long COVID could point the way to better understanding and ultimately better diagnostics and treatments.”

In an analysis of the blood samples from the patients, Epstein-Barr and cytomegalovirus seemed to activate in response to inflammation rather than immune system suppression.  The researchers say this is a surprising new mechanism, challenging the prevailing view that chronic viral reactivation is primarily a consequence of immunosuppression. This finding demonstrates that reactivations occur frequently in apparently immunocompetent individuals during severe illness and in association with increased systemic inflammation.

In addition, the authors write, the findings “challenge the prevailing view that chronic viral reactivation is primarily a consequence of immunosuppression, demonstrating that reactivations occur frequently in immunocompetent individuals during severe illness and in association with increased systemic inflammation.” They also demonstrate persistence of viral reactivation in convalescence and report an association of Anelloviridae with long COVID.

“Although many no longer think of COVID being a problem, up to 50,000 Americans died of COVID in 2025-2026 respiratory season and some estimates suggest over 10 million U.S. adults suffer from long COVID,” says Levy. “We need to help these patients recover with the best outcomes.” He adds “Moreover, sooner or later, there may be another coronavirus pandemic, which means we need to learn all the lessons we can from COVID-19 to be better prepared.”

Next steps for this work will be to uncover how the immune system responds to these viruses over the course COVID-19, with the aim of identifying effective therapeutics and establishing the optimal timing of any interventions.

The post COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

Lilly confident in slow and steady Foundayo launch, as ex-US sales shine

Published

on

Foundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.

Continue Reading

Uncategorized

STAT+: Could poop pills be the next treatment for food allergies?

In an early-stage clinical trial, six participants with peanut allergy showed improved tolerance to small peanut exposures up to four months after they received fecal microbiome transplant using stool capsules. 

The results of the Phase 1 clinical trial, published in Science Translational Medicine on Wednesday, suggests fecal microbiome transplant has the potential to be a viable treatment option for peanut allergy, according to experts. 

“We, as the food allergy community, have been waiting for these results,” said Stephen Tilles, an allergist-immunologist and clinical professor at the University of Washington, who was not a part of this study. Tilles described the study findings as “very exciting,” even if it may not be “ready for prime time” yet. 

Continue to STAT+ to read the full story…

Read More

Published

on

In an early-stage clinical trial, six participants with peanut allergy showed improved tolerance to small peanut exposures up to four months after they received fecal microbiome transplant using stool capsules. 

The results of the Phase 1 clinical trial, published in Science Translational Medicine on Wednesday, suggests fecal microbiome transplant has the potential to be a viable treatment option for peanut allergy, according to experts. 

“We, as the food allergy community, have been waiting for these results,” said Stephen Tilles, an allergist-immunologist and clinical professor at the University of Washington, who was not a part of this study. Tilles described the study findings as “very exciting,” even if it may not be “ready for prime time” yet. 

Continue to STAT+ to read the full story…

Read More

Continue Reading
Advertisement

Trending